Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Smallcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Biotech Limited has filed its quarterly financial results with the NSE for the period ended September 30, 2025, which corresponds to the second quarter of FY26. The filing announcement itself is a standard regulatory disclosure confirming that results have been submitted, without any specific numbers disclosed in this notice. The detailed financial figures, including revenue, profit after tax, EBITDA, and any auditor observations, would be contained in the actual results document. Investors should review the full financial statement for segment performance, margins, and year-on-year comparisons.
The submission is a routine compliance filing and does not itself move the stock; however, the underlying numbers in the submitted results could materially affect short-term price action and earnings expectations.